Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIWH 3 in chronic critical limb ischaemia
NCT02215824Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2002
- Primary completion
- Oct 2003
01
Overview
Phase 1, randomised, double-blind trial in critical limb ischemia (CLI) and Peripheral Arterial Disease (PAD) comparing BIWH 3 with Placebo (2 arms). Primary endpoints: Adverse events at 180 days, Vital signs at 180 days and 8 more. Started Oct 2002; status: terminated.
02
Drugs
BIWH 3
03
Conditions
critical limb ischemia (CLI)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02215824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215824.